201 related articles for article (PubMed ID: 38287839)
21. Multipotent Mesenchymal Stromal Cells in Rheumatoid Arthritis and Systemic Lupus Erythematosus; From a Leading Role in Pathogenesis to Potential Therapeutic Saviors?
El-Jawhari JJ; El-Sherbiny Y; McGonagle D; Jones E
Front Immunol; 2021; 12():643170. PubMed ID: 33732263
[TBL] [Abstract][Full Text] [Related]
22. Metabolic reprogramming as a key regulator in the pathogenesis of rheumatoid arthritis.
Cai WW; Yu Y; Zong SY; Wei F
Inflamm Res; 2020 Nov; 69(11):1087-1101. PubMed ID: 32797249
[TBL] [Abstract][Full Text] [Related]
23. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
Brown S; Everett CC; Naraghi K; Davies C; Dawkins B; Hulme C; McCabe C; Pavitt S; Emery P; Sharples L; Buch MH
Health Technol Assess; 2018 Jun; 22(34):1-280. PubMed ID: 29900829
[TBL] [Abstract][Full Text] [Related]
24. Lessons From the Success and Failure of Targeted Drugs for Rheumatoid Arthritis: Perspectives for Effective Basic and Translational Research.
Kim M; Choe YH; Lee SI
Immune Netw; 2022 Feb; 22(1):e8. PubMed ID: 35291656
[TBL] [Abstract][Full Text] [Related]
25. The effect of targeted rheumatoid arthritis therapies on anti-citrullinated protein autoantibody levels and B cell responses.
Modi S; Soejima M; Levesque MC
Clin Exp Immunol; 2013 Jul; 173(1):8-17. PubMed ID: 23607804
[TBL] [Abstract][Full Text] [Related]
26. The Role of Biologics in Rheumatoid Arthritis: A Narrative Review.
Patel JP; Konanur Srinivasa NK; Gande A; Anusha M; Dar H; Baji DB
Cureus; 2023 Jan; 15(1):e33293. PubMed ID: 36606106
[TBL] [Abstract][Full Text] [Related]
27. Rheumatoid arthritis: pathogenesis and therapeutic advances.
Gao Y; Zhang Y; Liu X
MedComm (2020); 2024 Mar; 5(3):e509. PubMed ID: 38469546
[TBL] [Abstract][Full Text] [Related]
28. Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection.
Biggioggero M; Crotti C; Becciolini A; Favalli EG
Drug Des Devel Ther; 2019; 13():57-70. PubMed ID: 30587928
[TBL] [Abstract][Full Text] [Related]
29. Signaling pathways in rheumatoid arthritis: implications for targeted therapy.
Ding Q; Hu W; Wang R; Yang Q; Zhu M; Li M; Cai J; Rose P; Mao J; Zhu YZ
Signal Transduct Target Ther; 2023 Feb; 8(1):68. PubMed ID: 36797236
[TBL] [Abstract][Full Text] [Related]
30. Novel Therapeutic Approaches in Rheumatoid Arthritis: Role of Janus Kinases Inhibitors.
Rivellese F; Lobasso A; Barbieri L; Liccardo B; de Paulis A; Rossi FW
Curr Med Chem; 2019; 26(16):2823-2843. PubMed ID: 29424301
[TBL] [Abstract][Full Text] [Related]
31. The type I IFN system in rheumatoid arthritis.
Conigliaro P; Perricone C; Benson RA; Garside P; Brewer JM; Perricone R; Valesini G
Autoimmunity; 2010 Apr; 43(3):220-5. PubMed ID: 20166872
[TBL] [Abstract][Full Text] [Related]
32. Where do T cells stand in rheumatoid arthritis?
Fournier C
Joint Bone Spine; 2005 Dec; 72(6):527-32. PubMed ID: 16087382
[TBL] [Abstract][Full Text] [Related]
33. Effects of Biological/Targeted Therapies on Bone Mineral Density in Inflammatory Arthritis.
Chen TL; Chang KH; Su KY
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35456929
[TBL] [Abstract][Full Text] [Related]
34. Identification of biomarkers in patients with rheumatoid arthritis responsive to DMARDs but with progressive bone erosion.
Marasco E; Fabbriciani G; Rotunno L; Longhi M; De Luca P; de Girolamo L; Colombini A
Front Immunol; 2023; 14():1254139. PubMed ID: 37809106
[TBL] [Abstract][Full Text] [Related]
35. Biomaterial-based immunotherapeutic strategies for rheumatoid arthritis.
Tu AB; Lewis JS
Drug Deliv Transl Res; 2021 Dec; 11(6):2371-2393. PubMed ID: 34414564
[TBL] [Abstract][Full Text] [Related]
36. PAPA Syndrome: Challenges in Achieving Long-Term Remission.
Smajlović H; Prohić A
Acta Dermatovenerol Croat; 2023 Nov; 31(2):106-109. PubMed ID: 38006373
[TBL] [Abstract][Full Text] [Related]
37. Rheumatoid arthritis: Biological therapy other than anti-TNF.
Rossi D; Modena V; Sciascia S; Roccatello D
Int Immunopharmacol; 2015 Aug; 27(2):185-8. PubMed ID: 25840282
[TBL] [Abstract][Full Text] [Related]
38. Metabolic Checkpoints in Rheumatoid Arthritis.
Pucino V; Certo M; Varricchi G; Marone G; Ursini F; Rossi FW; De Paulis A; Mauro C; Raza K; Buckley CD
Front Physiol; 2020; 11():347. PubMed ID: 32362840
[TBL] [Abstract][Full Text] [Related]
39. JAK/STAT pathway in pathology of rheumatoid arthritis (Review).
Ciobanu DA; Poenariu IS; Crînguș LI; Vreju FA; Turcu-Stiolica A; Tica AA; Padureanu V; Dumitrascu RM; Banicioiu-Covei S; Dinescu SC; Boldeanu L; Siloși I; Ungureanu AM; Boldeanu MV; Osiac E; Barbulescu AL
Exp Ther Med; 2020 Oct; 20(4):3498-3503. PubMed ID: 32905201
[TBL] [Abstract][Full Text] [Related]
40. Vitamin D Deficiency and Rheumatoid Arthritis.
Ishikawa LLW; Colavite PM; Fraga-Silva TFC; Mimura LAN; França TGD; Zorzella-Pezavento SFG; Chiuso-Minicucci F; Marcolino LD; Penitenti M; Ikoma MRV; Sartori A
Clin Rev Allergy Immunol; 2017 Jun; 52(3):373-388. PubMed ID: 27484684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
